OncoPharm Axitinib's Big Weekend
6 snips
Feb 21, 2019 Discover the latest breakthroughs in renal cell carcinoma treatments stemming from the ASCO Genitourinary symposium. Learn how the combination of pembrolizumab and axitinib is reshaping survival rates and responses, despite some treatment-related toxicities. Delve into darolutamide, a new androgen antagonist, and its anticipated FDA approval. The conversation also highlights important drug interactions with statins, particularly for older men with prostate cancer, inviting thoughts on future oncology pharmacy discussions.
AI Snips
Chapters
Transcript
Episode notes
Immunotherapy Plus VEGF Strategy
- Combining immunotherapy with VEGF inhibition became a major strategy in first-line renal cell carcinoma.
- Early trials suggested combinations might improve progression-free survival and overall outcomes.
Risk-Dependent Immunotherapy Benefit
- Nivolumab plus ipilimumab outperformed sunitinib for intermediate and poor-risk patients.
- Favorable-risk patients did better with sunitinib alone in that trial.
Risk Scores Guide Treatment Choice
- IMDC and MSKCC risk scores use overlapping clinical and lab variables to stratify RCC prognosis.
- These classifications guide first-line treatment choices and trial subgrouping.